Lotesurge Ophthalmic Suspension contains Loteprednol etabonate 0.5% w/v, a corticosteroid indicated for the treatment of inflammation and pain associated with ocular conditions such as postoperative inflammation following ocular surgery, allergic conjunctivitis, and anterior uveitis. Loteprednol etabonate exhibits potent anti-inflammatory activity by inhibiting the release of inflammatory mediators and reducing leukocyte infiltration, thereby alleviating symptoms such as redness, swelling, and discomfort. The formulation is designed as a sterile ophthalmic suspension to ensure optimal ocular bioavailability and patient comfort. Lotesurge should be administered as directed by a healthcare professional, typically instilled into the conjunctival sac with careful avoidance of contamination. Patients should be monitored for potential corticosteroid-related adverse effects, including increased intraocular pressure, delayed wound healing, and secondary ocular infections. Prolonged use may necessitate periodic intraocular pressure assessments to detect steroid-induced glaucoma. Lotesurge Ophthalmic Suspension is contraindicated in viral, fungal, or mycobacterial ocular infections and in patients with known hypersensitivity to any component of the formulation. Proper patient counseling on adherence, hygiene, and reporting of adverse effects is essential to maximize therapeutic outcomes and minimize risks.